Eyenovia announces fda approval of coastline international as contract manufacturer to initiate mydcombi commercial production

New york, nov. 02, 2023 (globe newswire) -- eyenovia, inc. (nasdaq: eyen), an ophthalmic technology company commercializing mydcombi™ for mydriasis, preparing for regulatory approval of app13007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that the fda has approved eyenovia's supplemental new drug application (snda), adding coastline international as a contract manufacturer. coastline will manufacture cartridge subassemblies for mydcombi, the only fda-approved tropicamide and phenylephrine hydrochloride fixed combination for mydriasis (office-based pupil dilation).
EYEN Ratings Summary
EYEN Quant Ranking